Illumina, Inc. (NASDAQ:ILMN) – Leerink Swann boosted their Q3 2017 earnings per share estimates for Illumina in a research note issued on Tuesday. Leerink Swann analyst P. Souda now expects that the life sciences company will earn $1.01 per share for the quarter, up from their previous estimate of $0.99. Leerink Swann has a “Outperform” rating and a $225.00 price target on the stock.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14. The company had revenue of $662.00 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.86 EPS. COPYRIGHT VIOLATION WARNING: “Q3 2017 EPS Estimates for Illumina, Inc. Boosted by Analyst (ILMN)” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/16/q3-2017-eps-estimates-for-illumina-inc-boosted-by-analyst-ilmn.html.

ILMN has been the topic of several other reports. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective on the stock. in a report on Wednesday, June 21st. Barclays PLC reiterated a “hold” rating and issued a $150.00 price objective on shares of Illumina in a report on Wednesday, July 19th. BidaskClub downgraded shares of Illumina from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 25th. Argus upped their price objective on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 price objective on the stock in a report on Thursday, July 27th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $181.76.

Shares of Illumina (NASDAQ:ILMN) opened at 210.72 on Thursday. The firm has a 50-day moving average of $197.88 and a 200 day moving average of $180.42. Illumina has a 52-week low of $119.37 and a 52-week high of $214.04. The firm has a market capitalization of $30.77 billion, a price-to-earnings ratio of 42.28 and a beta of 0.81.

In other news, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57. Following the completion of the transaction, the senior vice president now owns 24,908 shares of the company’s stock, valued at $5,263,807.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $174.24, for a total transaction of $25,264.80. Following the completion of the transaction, the senior vice president now directly owns 10,646 shares of the company’s stock, valued at approximately $1,854,959.04. The disclosure for this sale can be found here. Insiders have sold 195,434 shares of company stock worth $37,480,647 over the last quarter. Corporate insiders own 1.60% of the company’s stock.

Several hedge funds have recently bought and sold shares of ILMN. Winslow Capital Management LLC bought a new position in shares of Illumina in the second quarter worth about $211,584,000. HPM Partners LLC lifted its holdings in shares of Illumina by 29,103.8% in the second quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after acquiring an additional 749,424 shares during the last quarter. Fred Alger Management Inc. lifted its holdings in shares of Illumina by 611.9% in the second quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after acquiring an additional 548,030 shares during the last quarter. TIAA CREF Investment Management LLC lifted its holdings in shares of Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after acquiring an additional 527,548 shares during the last quarter. Finally, Capital World Investors lifted its holdings in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after acquiring an additional 410,000 shares during the last quarter. 93.34% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.